The Fallacy of the Metabolic Proxy

For three decades, the longevity field has been captivated by the "metabolic proxy" model—the idea that Caloric Restriction (CR) extends lifespan by hitting nutrient sensors like SIRT1 and AMPK to flip a cellular preservation switch. This concept has fueled a multi-billion dollar industry built on NAD+ precursors and sirtuin activators. However, I suspect these metabolic shifts are secondary, or even incidental, to a more fundamental structural gatekeeper: the acetylation-dependent activation threshold of the NLRP3 inflammasome.

Recent evidence suggests CR’s most profound impact on inflammaging is actually mediated by SIRT2-dependent deacetylation of the NLRP3 PYD domain at residues K21/K22 He et al., 2020. I’m proposing that the "aging" of the immune system isn't necessarily a result of increased inflammatory stimuli. Instead, it’s a dramatic lowering of the thermodynamic barrier required for the inflammasome to assemble in the first place.

The Rheostat Hypothesis: Acetylation as a Sensitivity Switch

In the canonical model, NLRP3 activation is triggered by potassium (K⁺) efflux. My hypothesis posits that acetylation status acts as a rheostat for this K⁺ threshold.

1. The Young/CR State: High SIRT2 activity keeps NLRP3 deacetylated. In this configuration, the PYD domain has a low affinity for ASC. You need a high-magnitude K⁺ efflux—the kind you'd get from an acute pathogen—to overcome the structural barrier and trigger assembly.
2. The Aged State: As SIRT2 declines, K21/K22 becomes hyperacetylated. This post-translational modification induces a conformational shift that increases binding affinity for ASC, effectively lowering the $K_d$ of the interaction.

Consequently, in the aged model, the "chronic leak" of K⁺ caused by mitochondrial decay or age-related membrane permeability is suddenly enough to trigger ASC speck formation and IL-1β release Latz et al., 2017. The inflammasome isn’t "overactive" in the traditional sense; it has simply become hypersensitive to baseline noise. CR works not by "fixing" metabolism, but by keeping the safety on the inflammasome trigger through SIRT2.

Methionine, Not Calories, as the SIRT2 Driver?

Expanding on the idea that caloric restriction might actually be a misnomer for methionine restriction (MR), I suggest that CR’s efficacy is tied to the availability of acetate and NAD+ specifically within the macrophage micro-environment. Methionine restriction modulates the sulfur-amino acid pathway and indirectly influences NAD+ salvage. If MR maintains SIRT2 activity more effectively than generalized calorie cutting, it would explain why MR replicates CR benefits without the energy deficit. The longevity industry’s obsession with SIRT1-mediated metabolic reprogramming might be targeting a downstream symptom of a system where the real damage is done by "leaky" inflammasomes that have lost their acetylation-gated structural integrity Youm et al., 2020.

Proposed Test and Falsifiability

To test this, we need to decouple K⁺ efflux from acetylation status in aged primary macrophages.

• The Experiment: I'd subject aged macrophages (high acetylation) and CR macrophages (low acetylation) to a titrated gradient of K⁺ ionophores, such as nigericin, and measure the inflection point of ASC speck formation using live-cell imaging.
• Prediction: The "activation threshold"—the specific concentration of K⁺ required to trigger 50% ASC oligomerization—will be significantly lower in aged cells.
• Falsification: If restoring SIRT2 activity or deacetylating K21/K22 fails to shift that K⁺ threshold—meaning the cells still fire at the same level of ionic flux regardless of acetylation—then the Rheostat Hypothesis is wrong. In that case, CR’s benefits must lie in reducing the K⁺ leak itself (mitochondrial fidelity) rather than the sensitivity of the sensor.